Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

20 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Real-World Treatment Sequencing in Vulnerable Patients with Metastatic Colorectal Cancer: A Multicenter Retrospective Study.
Mitani S, Kito Y, Hino K, Kawakami K, Izawa N, Hanamura F, Yamamoto Y, Shoji H, Komori A, Boku S, Tsuchihashi K, Kato K, Nonagase Y, Matsumoto T, Furuta M, Kawakami H. Mitani S, et al. Among authors: nonagase y. Target Oncol. 2023 Sep;18(5):707-715. doi: 10.1007/s11523-023-00996-0. Epub 2023 Sep 5. Target Oncol. 2023. PMID: 37668815
A comparative study of curated contents by knowledge-based curation system in cancer clinical sequencing.
Sakai K, Takeda M, Shimizu S, Takahama T, Yoshida T, Watanabe S, Iwasa T, Yonesaka K, Suzuki S, Hayashi H, Kawakami H, Nonagase Y, Tanaka K, Tsurutani J, Saigoh K, Ito A, Mitsudomi T, Nakagawa K, Nishio K. Sakai K, et al. Among authors: nonagase y. Sci Rep. 2019 Aug 5;9(1):11340. doi: 10.1038/s41598-019-47673-9. Sci Rep. 2019. PMID: 31383922 Free PMC article.
A phase I dose-escalation study of eribulin and S-1 for metastatic breast cancer.
Sakiyama T, Tsurutani J, Iwasa T, Kawakami H, Nonagase Y, Yoshida T, Tanaka K, Fujisaka Y, Kurata T, Komoike Y, Nishio K, Nakagawa K. Sakiyama T, et al. Among authors: nonagase y. Br J Cancer. 2015 Mar 3;112(5):819-24. doi: 10.1038/bjc.2015.10. Epub 2015 Feb 5. Br J Cancer. 2015. PMID: 25654665 Free PMC article. Clinical Trial.
Clinical Application of the FoundationOne CDx Assay to Therapeutic Decision-Making for Patients with Advanced Solid Tumors.
Takeda M, Takahama T, Sakai K, Shimizu S, Watanabe S, Kawakami H, Tanaka K, Sato C, Hayashi H, Nonagase Y, Yonesaka K, Takegawa N, Okuno T, Yoshida T, Fumita S, Suzuki S, Haratani K, Saigoh K, Ito A, Mitsudomi T, Handa H, Fukuoka K, Nakagawa K, Nishio K. Takeda M, et al. Among authors: nonagase y. Oncologist. 2021 Apr;26(4):e588-e596. doi: 10.1002/onco.13639. Epub 2021 Jan 6. Oncologist. 2021. PMID: 33325566 Free PMC article.
Heregulin-expressing HER2-positive breast and gastric cancer exhibited heterogeneous susceptibility to the anti-HER2 agents lapatinib, trastuzumab and T-DM1.
Nonagase Y, Yonesaka K, Kawakami H, Watanabe S, Haratani K, Takahama T, Takegawa N, Ueda H, Tanizaki J, Hayashi H, Yoshida T, Takeda M, Chiba Y, Tamura T, Nakagawa K, Tsurutani J. Nonagase Y, et al. Oncotarget. 2016 Dec 20;7(51):84860-84871. doi: 10.18632/oncotarget.12743. Oncotarget. 2016. PMID: 27768588 Free PMC article.
20 results